BERLIN 2025 ESMO congress

LBA91

Patient (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm)

D.E. Rathkopf[1], N. Agarwal[2], J.N. Graff[3], S.K. Sandhu[4], E. Efstathiou[5], M. Ozguroglu[6], A.J.P.D.S. Gomes[7], K.M. Vianna[8], H. Luo[9], G.T. Gotto[10], H.H. Cheng[11], C.R. Varela[12], K.S. Gries[13], B. Baron[14], F. Shen[12], S.D. Mundle[15], S.A. McCarthy[12], D. Olmos[16], K.N. Chi[17], G. Attard[18]

[1] Medicine Department, Memorial Sloan Kettering Cancer Center, New York, United States of America, [2] Internal Medicine Department, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America, [3] Hematology/Oncology Department, Oregon Health & Science University and Knight Cancer Institute & Veterans Affairs Portland Health Care System, Portland, United States of America, [4] Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, [5] Genitourinary Oncology, Houston Methodist Cancer Center, Houston, United States of America, [6] Department of Internal Medicine, Division of Medical Oncology, Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Türkiye, [7] Clinical Oncology and Clinical Research, Liga Norte Riograndense Contra o Câncer, Natal, Brazil, [8] Clinical Oncology, Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil, [9] Urology Department, Chongqing University Cancer Hospital, Chongqing, China, [10] Department of Surgery and Department of Oncology, University of Calgary, Calgary, Canada, [11] Department of Medicine (Hematology and Oncology), Fred Hutchinson Cancer Center, University of Washington, Seattle, United States of America, [12] Oncology, Johnson & Johnson, Spring House, United States of America, [13] Patient Reported Outcomes, Johnson & Johnson, Raritan, United States of America, [14] Statistics & Decision Sciences, Johnson & Johnson, Leiden, Netherlands, [15] Global Medical Affairs, Johnson & Johnson, Raritan, United States of America, [16] Medical Oncology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, [17] Department of Medical Oncology, BC Cancer – Vancouver Center, University of British Columbia, Vancouver, Canada[18] Research Department of Oncology, Cancer Institute, University College London, London, United Kingdom

Background

AMPLITUDE established efficacy of NIRA + AA + P vs AA + P in HRRm mHSPC, prolonging radiographic progression-free survival (rPFS, primary end point; final analysis) and showing significant improvement in time to symptomatic progression and favorable effect on overall survival (key secondary end points; first interim analysis). The NIRA + AA + P safety profile was consistent with prior experience. Here we assess PROs in the HRRm population.

Methods

Pts with HRRm mHSPC (≤6 mo androgen deprivation therapy, ± ≤6 cycles docetaxel, ± ≤45 d AA + P allowed as prior treatments [tmt]) were randomized 1:1 to receive dual-action tablet (NIRA 200 mg + AA 1000 mg) plus P 5 mg PO QD or placebo + AA + P QD in 28 d cycles. PRO instruments were FACT-P, EQ-5D-5L, and BPI-SF. PRO e-questionnaires were completed at screening, cycles 1-25, then Q4M up to 12 mo after end of tmt. PROs were analyzed by LS mean change from BL (mixed effect repeated measures model) and time to deterioration by Kaplan-Meier methods during tmt.

Results

Overall questionnaire completion compliance was ≥94.3%. Overall LS mean change from BL (SE) in FACT-G did not reveal clinically meaningful difference between arms: NIRA + AA + P 0.02 (0.50), AA + P 0.77 (0.50); p=0.3. During cycles 2-4, FACT-G scores decreased slightly with NIRA + AA + P and increased slightly with AA + P from BL with significant between-arm differences (p<0.05) but change in neither arm was clinically meaningful vs BL; from cycle 5, scores remained consistent with BL. FACT-P total score results were similar. Most pts (NIRA + AA + P 76-85%, AA + P 86-93%) were “not at all” or “a little bit” bothered by tmt side effects (FACT-P GP5, BL to cycle 41). LS mean change from BL (SE) in EQ-5D-5L VAS showed no difference between arms overall (NIRA + AA + P 1.82 [0.63], AA + P 2.59 [0.63]; p=0.4) and by cycle. Time to progression in BPI-SF worse pain intensity score was not different between arms (HR 0.95; 95% CI 0.72-1.26; p=0.7) and the medians were not reached.

Conclusions

In HRRm mHSPC, NIRA + AA + P maintained BL HRQoL with no clinically meaningful changes while significantly improving rPFS vs AA + P.

Clinical trial identification

NCT04497844.

Editorial acknowledgement

Writing assistance was provided by Breanne Landry, PhD, of Parexel, and was funded by Johnson & Johnson.

Legal entity responsible for the study

Janssen Research & Development, LLC, a Johnson & Johnson company.

Funding

Johnson & Johnson.

Disclosure

D.E. Rathkopf: Financial Interests, Personal, Advisory Board: curium; Financial Interests, Trial Chair: Janssen; Financial Interests, Steering Committee Member: Janssen, Bristol Myers Squibb International; Financial Interests, Institutional, Research Grant, Clinical Trial Grant: Genentech; Financial Interests, Research Grant, Drug provided for study: AstraZeneca, Bristol Myers Squibb International; Non-Financial Interests, Advisory Role: Janssen, Genentech, AstraZeneca, Myovant, Bayer, BMS; Non-Financial Interests, Principal Investigator: Janssen, Genentech, Promontory, BMS, Pfizer. N. Agarwal: Financial Interests, Personal, Invited Speaker, Invited speaker: Medscape; Financial Interests, Personal, Invited Speaker, Invited Speaker: Onclive, Research to Practice, Clinical Care Options; Financial Interests, Personal, Other, Urotoday discussant: UroToday; Financial Interests, Institutional, Other, I serve in the leadership of my cancer center (Huntsman Cancer Institute, University of Utah. Salt Lake City, UT, USA). There are multiple research projects sponsored by these companies which pay money to my institution.: Arnivas, Astellas, AstraZeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, Telix, Tracon.; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharmas with no personal honorarium.: AstraZeneca, Calithera, Crispr, Eli Lilly, Exelixis, Immunomedics, Merck, Pfizer,; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharma companies with no personal honorarium.: Merck, Nektar, New Link Genetics, Oric, Pfizer, Prometheus, Rexahn, Takeda, Telix,Tracon; Financial Interests, Trial Chair, One of the two co-chairs of the clinical trials sponsored by these pharma companies. I have not received any honorarium for these roles.: Pfizer, Exelixis, Janssen, Telix, AstraZeneca; Non-Financial Interests, Member, I am a long-standing member of ASCO and a volunteer. I was awarded the fellow of ASCO in 2023. I also act as the editor of the ASCO Daily News as a volunteer.: Amercian Society of Clinical Oncology; Non-Financial Interests, Member, I am a member of this NCI and NCTN-sponsored cooperative clinical trial network group.: SWOG; Non-Financial Interests, Member, I am a member of these professional organizations.: AACR, AUA, PCF. J.N. Graff: Financial Interests, Personal, Invited Speaker, CME vendor: P3; Financial Interests, Personal, Invited Speaker, CME: Binaytara Foundation; Financial Interests, Personal, Other, Testicular cancer chair-make around $7,000 USD per year: Elsevier; Financial Interests, Personal, Advisory Board: USPCCC; Financial Interests, Personal, Other, Testicular cancer chair: Elsevier; Financial Interests, Institutional, Coordinating PI, Two Investigator initiated, lead in a phase 3 trial (KN 641), local PI for several studies: Merck Sharpe Dohme; Financial Interests, Institutional, Steering Committee Member: Janssen, Curium; Financial Interests, Institutional, Coordinating PI: Sanofi; Financial Interests, Institutional, Funding: Prostate Cancer Foundation; Non-Financial Interests, Leadership Role: Veterans Affairs Hospital. S.K. Sandhu: Financial Interests, Institutional, Advisory Board, I have served on advisory boards for MSD. The e contracts for my role are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre.: Merck Sharp and Dohme; Financial Interests, Institutional, Advisory Board, I have served on advisory boards for AstraZeneca. The contracts for my role as an advisor are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre.: AstraZeneca; Financial Interests, Institutional, Advisory Board, I have served on advisory boards for Novartis. The contracts for my role as an advisor are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre.: Novartis; Financial Interests, Institutional, Advisory Board, I have served on an advisory board for Merck Serono. The contracts for my service are set up with the institution and funds go into a research fund at the Peter MacCallum Cancer Centre.: Merck Serono; Financial Interests, Institutional, Advisory Board, I have served on an advisory board for SkylineDx. The contracts for my service are set up with the institution and funds go into a research fund at the Peter MacCallum Cancer Centre.: SkylineDx; Financial Interests, Institutional, Advisory Board, I have served on an advisory board for AbbVie. The contracts for my role are with the institution and funds go into a research fund at the Peter MacCallum Cancer Centre.: AbbVie; Financial Interests, Institutional, Invited Speaker, I have received honoraria for invited speaker role only which is paid to my institution. Funds go into a research fund at the Peter MacCallum Cancer Centre.: Janssen; Financial Interests, Institutional, Advisory Board, I serve on an advisory board for AdvanCell. The contracts for my role are with the institution and funds go into a research fund at the Peter MacCallum Cancer Centre.: AdvanCell; Financial Interests, Personal, Stocks/Shares: AdvanCell; Financial Interests, Institutional, Research Grant, My institution receives grant funding to run an investigator initiated trial that I lead.: Novartis, Genentech, Amgen, AstraZeneca, Merck Serono, Merck Sharp and Dohme; Financial Interests, Institutional, Research Grant, Pfizer are providing funding to my institution for the conduct of an investigator initiated clinical trial.: Pfizer; Financial Interests, Institutional, Research Grant, Senwha are providing funding to my institution for the conduct of an investigator initiated clinical trial.: Senwha; Non-Financial Interests, Other, I serve on the Independent Safety and Data Monitoring committee for 2 of Novartis sponsored studies and dont receive any compensation for this.: Novartis; Non-Financial Interests, Other, I serve on the steering committee for several Janssen sponsored trials and i do not receive compensation for this.: Janssen; Non-Financial Interests, Other, I serve on the steering committee for

one AstraZeneca sponsored trial and I do not receive compensation for this.: AstraZeneca; Non-Financial Interests, Other, I serve on the steering committee for one Genentech sponsored trials and I do not receive compensation for this.: Genentech; Non-Financial Interests, Other, I serve on the steering committee for a Bristol Myer Squibb sponsored trial and I do not receive renumeration for this.: Bristol Myer Squibb; Non-Financial Interests, Principal Investigator, I am a principal investigator on several of Janssen sponsored studies and don't receive any renumeration for this.: Janssen; Non-Financial Interests, Principal Investigator, I am a principal investigator on several Novartis sponsored studies and dont receive any renumeration for this.: Novartis; Non-Financial Interests, Principal Investigator, I am a principal investigator on several of Genentech sponsored studies and don't receive any renumeration for this.: Genentech; Non-Financial Interests, Principal Investigator, I am a principal investigator on several of Bristol Myer Squibb sponsored studies and don't receive any renumeration for this.: Bristol Myer Squibb; Non-Financial Interests, Principal Investigator, I am the Priincipal Investigator for several AstraZeneca sponsored studies and am not remunerated for this.: AstraZeneca; Non-Financial Interests, Principal Investigator, I am a principal investigator on a MacroGenics sponsored study and don't receive any renumeration for this.: MacroGenics; Non-Financial Interests, Principal Investigator, I am a principal investigator on a Regeneron sponsored study and do not receive any renumeration for this.: Regeneron; Non-Financial Interests, Principal Investigator, I am the Principal Investigator on several Merck Sharp and Dohme studies and I do not receive any renumeration for this.: Merck Sharp and Dohme; Non-Financial Interests, Principal Investigator, I am a principal investigator on an IO Biotech study and I do not receive any renumeration for this.: IO Biotech; Non-Financial Interests, Principal Investigator, I am principal investigator on an Evaxion sponsored study and I do not receive any renumeration for this.: Evaxion; Non-Financial Interests, Advisory Role: Daiichi Sankyo, Erasca, Synolo Therapeutics, Macrogenics. E. Efstathiou: Financial Interests, Personal, Other, Honoraria: Pfizer, Bayer, Myovant, Sumitomo,AstraZeneca; Financial Interests, Personal, Advisory Role, Consulting or advisory role: JNJ, Pfizer, Astellas, Merck AstraZeneca, Tolmar; Financial Interests, Personal, Research Funding: Merck, Astellas, JNJ, Pfizer, AstraZeneca. M. Ozguroglu: Financial Interests, Personal, Advisory Board, prostate cancer: Astellas; Financial Interests, Personal, Invited Speaker, travel and accommodation: Regeneron; Financial Interests, Personal, Advisory Board, lung cancer meeting: sanofi. A.J.P.D.S. Gomes: Financial Interests, Personal, Invited Speaker: Astellas, Bayer, Janssen, AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer, Janssen. K.M. Vianna: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Adium Pharma; Financial Interests, Personal, Advisory Board, Consulting or advisory role: Roche/Genentech, AstraZeneca; Financial Interests, Personal, Speaker's Bureau: Roche/Genentech, AstraZeneca, Pfizer, GSK, Knight Pharmaceuticals, Servier, BMS Brazil, Bayer; Financial Interests, Personal, Other, Travel, Accomodations, Expenses: MSD Oncology, Roche/Genentech, AstraZeneca; Financial Interests, Institutional, Research Funding: AstraZeneca, Roche/Genentech, Janssen Oncology, Bristol Myers Squibb Brazil, Lilly, BeiGene, MSD Oncology, Incyte, Seagen, Servier, Gilead Sciences. G.T. Gotto: Financial Interests, Personal, Advisory Board: Astellas, Bayer, Janssen, Merck, BMS, EMD Serono; Financial Interests, Personal, Invited Speaker: Astellas, Bayer, Janssen, Merck, AstraZeneca; Non-Financial Interests, Principal Investigator: Janssen, Bayer, Astellas, AstraZeneca, Pfizer, Ferring. H.H. Cheng: Financial Interests, Personal, Officer, Chief Scientific Officer for non-profit organization, BRCA Research and Cure Alliance (CureBRCA): BRCA Research and Cure Alliance (CureBRCA), Officer; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Research Grant: Clovis Oncology; Financial Interests, Institutional, Steering Committee Member, Steering committee and site PI with institutional research support: Janssen; Financial Interests, Institutional, Research Grant, Co-PI for IIT with research grant support to institution: Medivation, Sanofi Aventis; Financial Interests, Institutional, Local PI, Research funding to institution to conduct Ph1 Study: Promontory Therapeutics. C.R. Varela: Financial Interests, Personal, Full or part-time Employment, I am employed at Johnson and Johnson: Johnson and Johnson; Financial Interests, Institutional, Stocks/Shares, As an employee, I receive stocks.: Johnson and Johnson. K.S. Gries: Financial Interests, Institutional, Full or part-time Employment, Employee of Johnson & Johnson: Johnson and Johnson; Financial Interests, Institutional, Stocks/Shares, Stock holder for Johnson and Johnson: Johnson and Johnson. B. Baron: Financial Interests, Personal, Full or part-time Employment, Employee of Johnson & Johnson: Johnson and Johnson; Financial Interests, Institutional, Stocks/Shares, Stock Holder for Johnson & Johnson: Johnson and Johnson. F. Shen: Financial Interests, Personal, Full or part-time Employment, Employee of Johnson & Johnson: Johnson & Johnson; Financial Interests, Institutional, Stocks/Shares, Stock Holder for Johnson & Johnson: Johnson & Johnson. S.D. Mundle: Financial Interests, Personal, Full or part-time Employment, Employee of Johnson and Johnson: Johnson and Johnson; Financial Interests, Institutional, Stocks/Shares, Stock Holder of Johnson and Johnson: Johnson and Johnson. S.A. Mccarthy: Financial Interests, Institutional, Full or part-time Employment: Johnson and Johnson; Financial Interests, Institutional, Stocks/Shares: Johnson and Johnson. D. Olmos: Financial Interests, Personal, Advisory Board: AstraZeneca, bayer, Johnson and Johnson, Pfizer, MSD, Merck Serono; Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Johnson and Johnson, Pfizer, MSD; Financial Interests, Personal, Member of Board of Directors: VDG Diagnostics; Financial Interests, Personal, Other, Inventor of a diagnostic NGS based test which transition from research to dignosis is performed by a Spin-off/Start-up from my prior institution: VDG diagnostics; Financial Interests, Institutional, Local PI: AstraZeneca, macrogenics, Johnson and Johnson, Merck Serono; Financial Interests, Personal and Institutional, Steering Committee Member: Bayer, Johnson and Johnson; Financial Interests, Institutional, Research Grant: AstraZeneca, Johnson and Johnson, Pfizer. K.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Novartis; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, AstraZeneca, BMS, Janssen, Merck, Novartis, Pfizer, Roche, Amgen; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Janssen, Novartis, BMS. G. Attard: Financial Interests, Personal, Invited Speaker: Janssen, Astellas, AstraZeneca, Sanofi; Financial Interests, Personal, Advisory Board: Janssen, Astellas, Novartis, Bayer, AstraZeneca, Pfizer, Sanofi, Sapience, Orion, Novartis, Blue Earth Therapeutics; Financial Interests, Personal, Other, Travel, accommodations, expenses: Amgen, Merck Serono, Pfizer; Financial Interests, Personal, Royalties, Included in list of rewards to discoverers of abiraterone: Institute of Cancer Research; Financial Interests, Institutional, Advisory Board: Artera, Veracyte; Financial Interests, Institutional, Research Grant: Janssen, Astellas, Novartis; Financial Interests, Institutional, Coordinating PI: Janssen; Financial Interests, Institutional, Local PI: Novartis, Pfizer; Financial Interests, Institutional, Funding: Blue Earth Therapeutics, Vercyte; Non-Financial Interests, Principal Investigator: Janssen, Astellas; Non-

Financial Interests, Advisory Role: Janssen, AstraZeneca, Amgen, Bayer, Blue Earth Therapeutics, Merck, Merck Serono, Novartis, Pfizer; Non-Financial Interests, Project Lead: Artera, Veracyte. All other authors have declared no conflicts of interest.